Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ABBV

What Are Wall Street Analysts' Target Price for Abbvie Stock?

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

Secure Decades of Passive Income: 3 Top Dividend Stocks to Buy Now

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.

Barchart

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the aging population. Hence, quality healthcare stocks, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co. (MRK), might be worth looking into. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Option Volatility And Earnings Report For July 22 - 26

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

Barchart

AbbVie Earnings Preview: What to Expect

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Barchart

3 Healthcare Stocks With Strong Profit Margins to Buy Now

The healthcare industry is poised to grow rapidly due to the rising need for medical aid, government initiatives, and increasing chronic diseases contributing to overall stability. Given the industry’s promising prospects, investors could consider buying quality healthcare stocks: UnitedHealth Group (UNH), Johnson & Johnson (JNJ), and AbbVie (ABBV), with strong…

StockNews.com

3 Undervalued Healthcare Stocks With High Potential

The healthcare sector is expected to grow rapidly due to the growing need for precision drugs, the rising elderly population, government initiatives, and increasing chronic diseases. Against this backdrop, investors could consider buying fundamentally strong, undervalued healthcare stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD). Read…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

Barchart

Down 14% from All-Time Highs, is This Dividend King a Buy on the Dip?

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Barchart

Abbvie Stock: Is Wall Street Bullish or Bearish?

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

Barchart

Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

StockNews.com

3 Defensive Stocks for 'Sell in May' Season

Investors can consider adding defensive stocks, such as AbbVie and Verizon, to their equity portfolios in 2024 to help shield against heightened stock market volatility.

Barchart

3 Pharma Stocks Delivering Exciting April Returns

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

StockNews.com

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Pharma Stocks Fueling Investor Enthusiasm

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

Barchart

The Best of the Best: The Top Dividend Aristocrats To Buy Now

Looking to add dividend aristocrats to your portfolio? These three are at the top of their game.

StockNews.com

Unleash Gain Potential With 3 Pharma Stocks to Consider

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

StockNews.com

Pharma Watchlist: 3 Stocks Worth Adding

The pharma industry embraces digital trends and advancements in clinical research in 2024, with prospects of significant expansion. Hence, fundamentally strong pharma stocks Dr. Reddy's Laboratories (RDY), Amneal Pharmaceuticals (AMRX), and AbbVie (ABBV) might be worth adding to one’s watchlist. Read more….

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

AbbVie (ABBV) Earnings Preview: Buy or Sell Opportunities

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

StockNews.com

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

StockNews.com

3 Pharma Powerhouses to Watch Closely

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Therefore, it could be wise to keep an eye on top pharma stocks, Roche Holding (RHHBY), Novartis (NVS) and AbbVie (ABBV). Continue reading.

StockNews.com

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

Barchart

3 Defensive Dividend Stocks to Protect Your Portfolio

Dividend-paying stocks are having a tough year, but there are still some top-rated income picks worth buying at current levels. Here's a look at three dividend stocks that can actually help defend your portfolio from market volatility.

StockNews.com

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

1 … 4 5 6 7

People

Dipanjan BanchurSince

722 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.